698 related articles for article (PubMed ID: 9884835)
21. Increasing in vitro resistance to fluconazole in Cryptococcus neoformans Cambodian isolates: April 2000 to March 2002.
Sar B; Monchy D; Vann M; Keo C; Sarthou JL; Buisson Y
J Antimicrob Chemother; 2004 Aug; 54(2):563-5. PubMed ID: 15254027
[TBL] [Abstract][Full Text] [Related]
22. Cryptococcus neoformans isolates from Yaoundé human immunodeficiency virus-infected patients exhibited intra-individual genetic diversity and variation in antifungal susceptibility profiles between isolates from the same patient.
Kammalac Ngouana T; Drakulovski P; Krasteva D; Kouanfack C; Reynes J; Delaporte E; Boyom FF; Mallié M; Bertout S
J Med Microbiol; 2016 Jul; 65(7):579-589. PubMed ID: 27100672
[TBL] [Abstract][Full Text] [Related]
23. Antifungal susceptibility testing with YeastONE™ is not predictive of clinical outcomes of Cryptococcus neoformans var. grubii fungemia.
Yang JH; Huang PY; Cheng CW; Shie SS; Lin ZF; Yang LY; Lee CH; Wu TS
Med Mycol; 2021 Nov; 59(11):1114-1121. PubMed ID: 34374784
[TBL] [Abstract][Full Text] [Related]
24. Treatment of acute cryptococcal meningitis in HIV infected adults, with an emphasis on resource-limited settings.
Sloan D; Dlamini S; Paul N; Dedicoat M
Cochrane Database Syst Rev; 2008 Oct; (4):CD005647. PubMed ID: 18843697
[TBL] [Abstract][Full Text] [Related]
25. In vitro susceptibilities of Malaysian clinical isolates of Cryptococcus neoformans var. grubii and Cryptococcus gattii to five antifungal drugs.
Tay ST; Tanty Haryanty T; Ng KP; Rohani MY; Hamimah H
Mycoses; 2006 Jul; 49(4):324-30. PubMed ID: 16784448
[TBL] [Abstract][Full Text] [Related]
26. Increased Antifungal Drug Resistance in Clinical Isolates of Cryptococcus neoformans in Uganda.
Smith KD; Achan B; Hullsiek KH; McDonald TR; Okagaki LH; Alhadab AA; Akampurira A; Rhein JR; Meya DB; Boulware DR; Nielsen K;
Antimicrob Agents Chemother; 2015 Dec; 59(12):7197-204. PubMed ID: 26324276
[TBL] [Abstract][Full Text] [Related]
27. Response to therapy in patients with cryptococcosis and AIDS: Association with in vitro susceptibility to fluconazole.
Agudelo CA; Muñoz C; Ramírez A; Tobón AM; de Bedout Bact C; Cano LE; Restrepo A
Rev Iberoam Micol; 2015; 32(4):214-20. PubMed ID: 25637338
[TBL] [Abstract][Full Text] [Related]
28. In-vitro susceptibility of Cryptococcus neoformans isolates to fluconazole and itraconazole.
Davey KG; Johnson EM; Holmes AD; Szekely A; Warnock DW
J Antimicrob Chemother; 1998 Aug; 42(2):217-20. PubMed ID: 9738839
[TBL] [Abstract][Full Text] [Related]
29. Combination therapy with fluconazole and flucytosine in the murine model of cryptococcal meningitis.
Nguyen MH; Najvar LK; Yu CY; Graybill JR
Antimicrob Agents Chemother; 1997 May; 41(5):1120-3. PubMed ID: 9145879
[TBL] [Abstract][Full Text] [Related]
30. The combination of tamoxifen with amphotericin B, but not with fluconazole, has synergistic activity against the majority of clinical isolates of Cryptococcus neoformans.
Hai TP; Van AD; Ngan NTT; Nhat LTH; Lan NPH; Vinh Chau NV; Thwaites GE; Krysan D; Day JN
Mycoses; 2019 Sep; 62(9):818-825. PubMed ID: 31173410
[TBL] [Abstract][Full Text] [Related]
31. Multi-centre evaluation of the Etest method for antifungal drug susceptibility testing of Candida spp. and Cryptococcus neoformans. BSAC Working Party on Antifungal Chemotherapy.
Warnock DW; Johnson EM; Rogers TR
J Antimicrob Chemother; 1998 Sep; 42(3):321-31. PubMed ID: 9786472
[TBL] [Abstract][Full Text] [Related]
32. Amphotericin B and fluconazole, a potent combination therapy for cryptococcal meningitis.
Larsen RA; Bauer M; Thomas AM; Graybill JR
Antimicrob Agents Chemother; 2004 Mar; 48(3):985-91. PubMed ID: 14982793
[TBL] [Abstract][Full Text] [Related]
33. Development of secondary resistance to fluconazole in Cryptococcus neoformans isolated from a patient with AIDS.
Alves SH; Lopes JO; Costa JM; Klock C
Rev Inst Med Trop Sao Paulo; 1997; 39(6):359-61. PubMed ID: 9674289
[No Abstract] [Full Text] [Related]
34. Relationship between intracranial pressure and antifungal agents levels in the CSF of patients with cryptococcal meningitis.
Wirth F; de Azevedo MI; Pilla C; Aquino VR; Neto GW; Goldani LZ
Med Mycol; 2018 Apr; 56(3):257-262. PubMed ID: 28992308
[TBL] [Abstract][Full Text] [Related]
35. Trends in antifungal drug susceptibility of Cryptococcus neoformans isolates obtained through population-based surveillance in South Africa in 2002-2003 and 2007-2008.
Govender NP; Patel J; van Wyk M; Chiller TM; Lockhart SR;
Antimicrob Agents Chemother; 2011 Jun; 55(6):2606-11. PubMed ID: 21444707
[TBL] [Abstract][Full Text] [Related]
36. Comparison of clinical and biological characteristics of HIV-infected patients presenting Cryptococcus neoformans versus C. curvatus/C. laurentii meningitis.
Zono B; Moutschen M; Situakibanza H; Sacheli R; Muendele G; Kabututu P; Biakabuswa A; Landu N; Mvumbi G; Hayette MP
BMC Infect Dis; 2021 Nov; 21(1):1157. PubMed ID: 34781895
[TBL] [Abstract][Full Text] [Related]
37. A systematic review of fluconazole resistance in clinical isolates of Cryptococcus species.
Bongomin F; Oladele RO; Gago S; Moore CB; Richardson MD
Mycoses; 2018 May; 61(5):290-297. PubMed ID: 29377368
[TBL] [Abstract][Full Text] [Related]
38. Molecular epidemiology reveals genetic diversity among 363 isolates of the Cryptococcus neoformans and Cryptococcus gattii species complex in 61 Ivorian HIV-positive patients.
Kassi FK; Drakulovski P; Bellet V; Krasteva D; Gatchitch F; Doumbia A; Kouakou GA; Delaporte E; Reynes J; Mallié M; Menan HIE; Bertout S
Mycoses; 2016 Dec; 59(12):811-817. PubMed ID: 27461533
[TBL] [Abstract][Full Text] [Related]
39. Development of azole resistance during fluconazole maintenance therapy for AIDS-associated cryptococcal disease.
Friese G; Discher T; Füssle R; Schmalreck A; Lohmeyer J
AIDS; 2001 Nov; 15(17):2344-5. PubMed ID: 11698718
[No Abstract] [Full Text] [Related]
40. Molecular subtypes and antifungal susceptibilities of serial Cryptococcus neoformans isolates in human immunodeficiency virus-associated Cryptococcosis. Cryptococcal Disease Active Surveillance Group.
Brandt ME; Pfaller MA; Hajjeh RA; Graviss EA; Rees J; Spitzer ED; Pinner RW; Mayer LW
J Infect Dis; 1996 Oct; 174(4):812-20. PubMed ID: 8843221
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
